<SEC-DOCUMENT>0001213900-25-116117.txt : 20251128
<SEC-HEADER>0001213900-25-116117.hdr.sgml : 20251128
<ACCEPTANCE-DATETIME>20251128164050
ACCESSION NUMBER:		0001213900-25-116117
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251128
DATE AS OF CHANGE:		20251128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACTELIS NETWORKS INC
		CENTRAL INDEX KEY:			0001141284
		STANDARD INDUSTRIAL CLASSIFICATION:	COMMUNICATIONS EQUIPMENT, NEC [3669]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				522160309
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-290758
		FILM NUMBER:		251536224

	BUSINESS ADDRESS:	
		STREET 1:		4039 CLIPPER COURT
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-545-1040

	MAIL ADDRESS:	
		STREET 1:		4039 CLIPPER COURT
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0267559-424b3_actelis.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Filed pursuant to Rule 424(b)(3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. 333-290758</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actelis Networks, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Up
to 10,635,265 </B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares of Common Stock</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the offer and sale from time to time of up to 10,635,265 shares of common stock of Actelis Networks, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our,&rdquo; the &ldquo;Company,&rdquo; or &ldquo;Actelis&rdquo;), par value $0.0001 per share (the &ldquo;Common Stock&rdquo;),
by White Lion Capital, LLC (&ldquo;White Lion&rdquo; or the &ldquo;Selling Stockholder&rdquo; or the &ldquo;selling stockholder&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities included in this prospectus consist of shares of Common Stock that we may, in our discretion, elect to issue and sell to the
Selling Stockholder,&nbsp; pursuant to (i) that certain Common Stock Purchase Agreement, dated as of September 27, 2025 and effective
as of October 1, 2025, by and between us and White Lion (the &ldquo;ELOC Purchase Agreement&rdquo;) establishing an equity line of credit,
and (ii) that certain Stock Purchase Agreement, dated as of September 27, 2025, by and between us and White Lion (the &ldquo;PIPE Purchase
Agreement&rdquo;) entered into in connection with a private placement of the Company&rsquo;s securities, which took place concurrently
with the establishment of the equity line of credit. Such shares of our Common Stock include up to (i) 10,000,000 shares of Common Stock
that we may elect, in our sole discretion, to issue and sell to White Lion, from time to time from and after the commencement date under
the ELOC Purchase Agreement, and, subject to applicable stock exchange rules, (ii) 284,091 shares of Common Stock issuable to White Lion
as commitment shares under the ELOC Purchase Agreement (based on a conversion price of $2.64 per share, the lowest traded price of our
common stock during the 30 business days prior to the date of issuance), (iii) 87,177 shares of Common Stock issued to the Selling Stockholder
pursuant to the PIPE Purchase Agreement and (iv) 263,997 shares of Common Stock issuable to the Selling Stockholder upon exercise of
Pre-Funded Warrants issued pursuant to the PIPE Purchase Agreement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The actual number of shares
of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to the selling stockholder
under the ELOC Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration
statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with the U.S. Securities and Exchange Commission
(the &ldquo;SEC&rdquo;). See &ldquo; White Lion Transaction&rdquo; for a description of the ELOC Purchase Agreement and the PIPE Purchase
Agreement and &ldquo;Selling Stockholder&rdquo; for additional information regarding White Lion.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are registering the shares
on behalf of the selling stockholder, to be offered and sold by it from time to time. We are not selling any securities under this prospectus,
and will not receive any proceeds from the sale of Common Stock by the selling stockholder pursuant to this prospectus. We may receive
up to $30.0 million in aggregate gross proceeds from White Lion under the ELOC Purchase Agreement in connection with sales of the shares
of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus. However, the
actual proceeds from White Lion may be less than this amount depending on the number of shares of our Common Stock sold and the price
at which the shares of our Common Stock are sold. The purchase price per share that White Lion will pay for shares of Common Stock purchased
from us under the ELOC Purchase Agreement will fluctuate based on the market price of our shares at the time we elect to sell shares
to White Lion and, further, to the extent that the Company sells shares of Common Stock under the ELOC Purchase Agreement, substantial
amounts of shares could be issued and resold, which would cause dilution and may impact the Company&rsquo;s stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of our shares of Common Stock in the public market by the selling stockholder and/or by our other existing securityholders, or the perception
that those sales might occur, could increase the volatility of and cause a significant decline in the market price of our securities
and could impair our ability to raise capital through the sale of additional equity securities. See &ldquo;<I>Sales of a substantial
number of our securities in the public market by the selling stockholder and/or by our existing securityholders could cause the price
of our shares of Common Stock and Warrants to fall.</I>&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All the securities offered
in this prospectus by the selling securityholder may be resold for so long as the registration statement, of which this prospectus forms
a part, is available for use. The sale of all or a portion of the securities being offered in this prospectus could result in a significant
decline in the public trading price of our securities. Despite such a decline in the public trading price, some of the selling securityholder
may still experience a positive rate of return on the securities they purchased due to the price at which such selling securityholder
initially purchased the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are registering the securities
for resale pursuant to the selling securityholder&rsquo;s registration rights under certain agreements between us, on the one hand, and
the selling securityholder, on the other hand, subject to certain exceptions. Our registration of the securities covered by this prospectus
does not mean that the selling securityholder will offer or sell any of the securities registered for resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will bear all costs, expenses,
and fees in connection with the registration of the shares of Common Stock. The selling securityholder may offer, sell or distribute
all or a portion of its shares of Common Stock publicly or through private transactions at prevailing market prices or at negotiated
prices. The selling securityholder will bear all commissions and discounts, if any, attributable to its sales of the shares of Common
Stock. We provide more information about how the selling securityholder may sell the shares of Common Stock in the section titled &ldquo;<I>Plan
of Distribution</I>.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus gives effect
to a 10-for-1 reverse share split of our issued and outstanding shares of common stock (the &ldquo;Reverse Split&rdquo;), which was effected
on November 18, 2025. Except where otherwise indicated, other than in the historical financial statements and related notes incorporated
by reference into this prospectus, all share and per share data in this prospectus have been retroactively restated to reflect the Reverse
Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is traded
on the Nasdaq Capital Market under the symbol &ldquo;ASNS.&rdquo; On November 26, 2025, the closing price of our Common Stock on the Nasdaq
Capital Market was $2.93 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well
as the information incorporated herein and therein by reference carefully before you make your investment decision. See &ldquo;Risk Factors&rdquo;
beginning on page 7 of this prospectus.</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is November 28, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward-Looking
    Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">iii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_014">White Lion Transaction</A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholder</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Offered Securities</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information
    by Reference</FONT></A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context indicates
otherwise, references in this prospectus to &ldquo;Actelis,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;the
Company,&rdquo; &ldquo;our company&rdquo; and similar terms refer to Actelis Networks, Inc., a Delaware corporation. Actelis has a wholly-owned
subsidiary, Actelis Networks Israel, Ltd, an Israeli company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The selling stockholder named
in this prospectus may from time to time sell the securities described in the prospectus. You should read this prospectus together with
the more detailed information regarding our company, our Common stock, and our financial statements and notes to those statements that
appear elsewhere in this prospectus and any applicable prospectus supplement together with the additional information that we incorporate
in this prospectus by reference, which we describe under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in, or incorporated by reference in, this prospectus and in any accompanying prospectus supplement. We have not
authorized anyone to provide you with different information from that contained in, or incorporated by reference in, this prospectus.
You should not assume that the information in this prospectus or any prospectus supplement is accurate as of any date other than the
date on the front of those documents or that any document incorporated by reference is accurate as of any date other than its filing
date. You should not consider this prospectus to be an offer or solicitation relating to the securities in any jurisdiction in which
such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider this prospectus to be
an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified to do so, or if it
is unlawful for you to receive such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and the documents
incorporated by reference herein contain certain &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities
Litigation Reform Act&nbsp;of&nbsp;1995, Section&nbsp;27A of the Securities Act&nbsp;of&nbsp;1933, as amended (the &ldquo;Securities
Act&rdquo;), and Section&nbsp;21E of the Securities Exchange&nbsp;Act&nbsp;of&nbsp;1934, as amended (the Exchange&nbsp;Act&rdquo;). We
have tried, whenever possible, to identify these forward-looking statements using words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;continue,&rdquo;
&ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo;
&ldquo;ongoing,&rdquo; and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These
statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements
involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to
differ materially from those expressed in, or implied by, such statements. Forward-looking statements contained herein include, but are
not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history of losses and
    need for additional capital to fund our operations and our ability to obtain additional capital on acceptable terms, or at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect
    our intellectual property and continue to innovate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success in retaining
    or recruiting, or changes required in, our officers, key employees or directors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential insufficiency
    of our disclosure controls and procedures to detect errors or acts of fraud;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accuracy of our estimates
    regarding expenses, future revenues, and capital requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing
    products or technologies that are or may become available;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing
    products or technologies that may become available;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to grow the
    business due to the uncertainty resulting from the COVID-19 pandemic or any future pandemic;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    complex and increasing regulations by governmental authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to regain and
    maintain compliance with continued listing requirements of the Nasdaq Capital Market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue
    as a going concern;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements as to the impact
    of the political and security situation in Israel on our business, including due to the number of armed conflicts between Israel
    and Hamas (an Islamist militia and political group in the Gaza Strip), Hezbollah (an Islamist militia and political group in Lebanon)
    and Iran;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our public securities&rsquo;
    potential liquidity and trading; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding
    the period during which we qualify as an emerging growth company under the JOBS Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are based on our management&rsquo;s current expectations, estimates, forecasts and projections about our business and the industry in
which we operate and our management&rsquo;s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of
our forward-looking statements herein may turn out to be inaccurate. Important factors that may cause actual results to differ materially
from current expectations include, among other things, those listed under &ldquo;Risk Factors,&rdquo; &ldquo;Use of Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; &ldquo;Business&rdquo; and elsewhere herein or by incorporation by reference.
Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. You should read thoroughly
this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different
from and worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances
reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus.
See &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 18, 2025, we
effected the Reverse Split. Except where otherwise indicated, other than in the historical financial statements and related notes incorporated
by reference into this prospectus, all share and per share data in this prospectus have been retroactively restated to reflect the Reverse
Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_003"></A><B>PROSPECTUS
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
information contained elsewhere in this prospectus. Because this is only a summary, it does not contain all of the information that may
be important to you. You should read this entire prospectus and should consider, among other things, the matters set forth under &ldquo;Risk
Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated
financial statements and related notes thereto appearing elsewhere in this prospectus before making your investment decision. This prospectus
contains forward-looking statements and information relating to Actelis Networks, Inc. See &ldquo;Cautionary Note Regarding Forward-Looking
Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actelis Networks, Inc. (&ldquo;Actelis,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our company&rdquo;) is a market leader in cyber-hardened,
rapid-deployment networking solutions for wide-area internet of things (&ldquo;IoT&rdquo;) applications including federal, state and
local government, intelligent traffic systems (&ldquo;ITS&rdquo;), military, utility, rail, telecom and campus applications. Our unique
portfolio of hybrid fiber, environmentally hardened aggregation switches, high density Ethernet devices, advanced management software
and cyber-protection capabilities, unlocks the hidden value of essential networks, delivering safer connectivity for rapid, cost-effective
deployment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our networking solutions
use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines which our patented technology can upgrade
to Fiber-grade to jointly create what we believe to be a highly cost-effective, secure, and quick-to-deploy network. Our patent protected
hybrid fiber networking solutions deliver excellent communication over fiber to locations that may be easy to reach with new fiber. However,
for locations that are difficult, or too costly to reach with fiber, we can upgrade existing copper lines to deliver cyber-hardened,
high-speed connectivity without needing to replace the existing copper infrastructure with new fiber. We believe that such hybrid fiber
copper networking solution has distinct advantages in most real-life installations, while providing significant budget savings and accelerating
deployment of modern IoT networks, as based on our experience, most IoT projects have challenging, hard to reach with fiber locations
which may explode such projects&rsquo; timeline and budgets. We believe that our solutions can provide connectivity over either fiber
or copper with speeds of up to multi-Gigabit communication, while supporting Fiber-grade reliability and quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary focus of ours is
to provide our customers with a cyber-secure network solution. We currently offer Triple-Shield protection of data delivered with coding,
scrambling and encryption of the network traffic. We also provide secure, encrypted access to our network management software, and are
working to further enhance system-level and device-level software protection. We are also working to introduce additional capabilities
for network-wide cyber protection software as an additional software and license-based services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When high speed, long reach,
reliable and secure connectivity is required, network operators usually resort to using wireline communication over physical communication
lines such as fiber, coax, and copper, rather than wireless communication that is more limited in performance, reliability, reach and
security. However, new fiber wireline infrastructure is costly to deploy, involves lengthy civil works to install, and, based on our
internal calculations, often accounts for more than 50% of total cost of ownership (ToC) and time to deploy wide-area IoT projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Providing new fiber connectivity
to hard-to-reach locations is especially costly and time-consuming, often requiring permits for boring, trenching, and right-of-way,
sometimes done over many miles. Connecting such hard-to-reach locations may cause significant delays and budget overruns in IoT projects.
Our solutions aim to solve these challenges by instantly enhancing performance of such existing copper and coax infrastructure to fiber-grade
performance, through the use of advanced signal processing and unique, patented network architecture, without the need to run new fiber
to hard-to-reach locations; thus, effectively accelerating deployment of many IoT projects, as we estimate, sometimes from many months
to only days. The result for the network owner is a hybrid network that optimizes the use of both new Fiber (where available) as well
as upgraded, fiber-grade copper and coax that is now modernized, digitized and cyber-hardened. This unique hybrid network approach is
making IoT projects often significantly more affordable, fast to deploy and predictable to plan and budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our solutions
can also provide power over existing copper and coax lines to remotely power up network elements and IoT components connected to them
(like cameras, small cell and Wi-Fi base stations sensors etc.). Connecting power lines to millions of IoT locations can be costly and
very time consuming as well (similar to data connectivity, for the same reason &mdash; need for civil works). By offering the ability
to combine power delivery over the same existing copper and coax lines that we use for high-speed data, we believe our solutions are
solving yet another important challenge in connecting hard-to-reach locations. We believe that combining communication and power over
the same existing lines is particularly important to help connect many fifth generation, or 5G, small cells and Wi-Fi base stations,
as high cost of connectivity and power is often slowing their deployment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, our
business was focused on serving telecommunication service providers, also known as Telcos, to provide connectivity for enterprises and
residential customers. Our products and solutions have been deployed with more than 100 telecommunication service providers worldwide,
in enterprise, residential and mobile base station connectivity applications. In recent years, as we have further developed our technology
and introduced additional products, we turned our focus on serving the wide-area IoT, federal and DoD markets, as well as multi-dwelling
units, and introduced, in 2024, our cyber-aware networking solutions for IoT markets as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>July 2025 Private Placement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2025, we entered
into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with certain accredited investors (the &ldquo;Investors&rdquo;),
pursuant to which we agreed to issue and sell to the Investors in a private placement (the &ldquo;July 2025 Private Placement&rdquo;
or the &ldquo;Offering&rdquo;) (a) 162,602 shares of Common Stock, (b) Series A-3 warrants to purchase up to 162,602 shares of Common
Stock, and (c) Series A-4 Warrants to purchase up to 325,204 shares of Common Stock, for a purchase price of $6.15 per share and related
Common Warrants, for a total aggregate gross proceeds of approximately $1 million. The July 2025 Private Placement closed on July 2,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A-3 Warrants have
an exercise price of $6.15 per share, are exercisable commencing on the effective date of shareholder approval (the &ldquo;Shareholder
Approval Date&rdquo;) of the issuance of the shares issuable upon exercise of the Common Warrants (&ldquo;Shareholder Approval&rdquo;)
and expire five years following the Shareholder Approval Date. On November 7, 2025, the Shareholder Approval was obtained in a special
meeting of our shareholders, resulting in the Shareholder Approval Date being such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A-4 Warrants have
an exercise price of $6.15 per share, are exercisable commencing on the Shareholder Approval Date and expire eighteen months following
the Shareholder Approval Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Common
Warrants, the Investors may not exercise the warrants to the extent such exercise would cause the Investor, together with its affiliates
and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% (or, at such Investor&rsquo;s
option upon issuance, 9.99%), of the Company&rsquo;s then outstanding Common Stock following such exercise, excluding for purposes of
such determination shares of Common Stock issuable upon exercise of such warrants which have not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">H.C. Wainwright &amp; Co.,
LLC acted as the Placement Agent for the issuance and sale of the Securities. The Company has agreed to pay an aggregate cash fee equal
to 7.0% of the gross proceeds received by the Company from the Offering and $35,000 for accountable expenses to the placement agent.
The Company also agreed to issue to the Placement Agent, or its designees, Placement Agent Warrants to purchase up to 7.0% of the aggregate
number of the shares of Common Stock sold to the Investors (or warrants to purchase up to 11,382 shares of Common Stock) at an exercise
price per share of $7.688 which will be exercisable commencing on the Shareholder Approval Date and a have term of five years after the
Shareholder Approval Date (the &ldquo;July 2025 Placement Agent Warrants,&rdquo; and collectively with the Common Warrants, the &ldquo;July
2025 Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The July 2025 Placement Agent
Warrants and the shares of Common Stock issuable upon exercise thereof, will be issued in reliance on the exemption from registration
provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions
under applicable state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Nasdaq Listing Compliance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 25, 2023, we received
a notification letter from the Listing Qualifications Staff (the &ldquo;Staff&rdquo;) of Nasdaq indicating that we are not in compliance
with Nasdaq Listing Rule 5550(b)(1) due to our failure to maintain a minimum of $2,500,000 in shareholders&rsquo; equity (the &ldquo;Minimum
Shareholders&rsquo; Equity Requirement&rdquo;) or any alternatives to such requirement. In order to maintain our listing on the Nasdaq
Capital Market, we submitted a plan of compliance addressing how we intended to regain compliance. On March 27, 2024, we received a delist
determination letter from Nasdaq advising us that the Staff had determined to delist our securities from Nasdaq due to non-compliance
with the Minimum Shareholders&rsquo; Equity Requirement, unless we timely request a hearing before the Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;).
We timely requested a hearing before the Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 27, 2024, we received
formal written notice from Nasdaq confirming that we have evidenced compliance with all applicable criteria for continued listing on
Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders&rsquo; Equity Requirement. In accordance with Nasdaq
Listing Rule 5815(d)(4)(B), we remained subject to a panel monitor for equity compliance through August 27, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 12, 2025, Nasdaq notified
us (the &ldquo;Notification Letter&rdquo;) that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires our Common
Stock to maintain a minimum bid price of $1.00 per share (the &ldquo;Bid Price Rule&rdquo;). The Notification Letter had no immediate
effect on the listing or trading of our Common Stock on Nasdaq and, at this time, the Common Stock will continue to trade on Nasdaq under
the symbol &ldquo;ASNS&rdquo;. The Notification Letter provided that we have 180 calendar days, or until November 10, 2025, to regain
compliance with the Bid Price Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 19, 2025, we received
written notice from Nasdaq stating&nbsp;that, due to the Company&rsquo;s non-compliance with the Minimum Shareholders&rsquo; Equity Requirement
as of June 30, 2025, and because, pursuant to Listing Rule 5815(d)(4)(B), the Company remained subject to a mandatory hearing panel monitor
through August 27, 2025, the Company&rsquo;s securities were subject to delisting from Nasdaq unless the Company timely requests a hearing
before the Nasdaq Hearing Panel (the &ldquo;Panel&rdquo;). The Company has its hearing with the Panel on September 30, 2025. At the hearing,
the Company presented its plan to evidence compliance with the Equity Rule and all other applicable criteria for continued listing on
The Nasdaq Capital Market, and requested to remain listed subject to its plan to regain compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 28, 2025, we received
a listing decision from Nasdaq notifying us that the Panel determined that the Company evidenced compliance with the Shareholders&rsquo;
Equity Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Panel also granted the
Company&rsquo;s request for continued listing on The Nasdaq Capital Market, pursuant to an exception through December 5, 2025, to regain
compliance with the bid price requirement set forth in Nasdaq Listing Rule 5550(a)(1). In order to evidence compliance with the bid price
requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10, but generally not more than
20, consecutive business days. On November 7, 2025, we held a special meeting of shareholders where our shareholders approved, among
other things, the Reverse Split. The Reverse Split was effected on November 18, 2025. Despite the fact that the Company&rsquo;s common
stock is now trading above $1.00, we cannot guarantee that our shares of common stock will maintain the closing bid price of $1.00 or
more for at least 10 consecutive business days thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will remain subject
to a one-year discretionary Panel Monitor through October 28, 2026. If during that period the Company fails to satisfy any of the criteria
for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550, the Staff may not grant the Company additional
time to regain compliance with respect to a deficiency nor will the Company be afforded a cure period under Nasdaq Listing Rule 5810(c)(3).
Rather, Nasdaq will issue a delist determination, which the Company may address by requesting a new hearing before the Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 12, 2025, we
received a letter from the Nasdaq Listing Qualifications Staff stating that, due to the Company&rsquo;s non-compliance with the Bid Price
Rule by the expiration of the 180-day grace period that expired on November 10, 2025, the Bid Price Rule forms a separate basis for delisting.
Notwithstanding, by letter dated October 28, 2025, the Panel granted the Company a further extension to regain compliance with the Bid
Price Rule through December 5, 2025. Based on the Company&rsquo;s compliance plan that was the basis for the Panel&rsquo;s October 28,
2025 decision, the Company believes that it will be in position to regain compliance with the Bid Price Rule by the Panel&rsquo;s December
5, 2025 deadline. As a result, the Company does not plan to make a further submission for the Hearings Panel consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>September 2025 Warrant
Inducement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 2, 2025, we
entered into an inducement agreement (the &ldquo;Inducement Letter&rdquo;) with a certain holder (the &ldquo;Holder&rdquo;) of certain
of the Company&rsquo;s existing warrants to purchase an aggregate of 427,020 shares of the Company&rsquo;s common stock, consisting of
(i) 127,119 warrants issued on December 20, 2023 with an expiration date of June 20, 2029 at an exercise price of $11.8 per share (ii)
99,967 warrants issued on June 6, 2024 with an expiration date of December 6, 2029 at an exercise price of $20.0 per share and (iii)
199,934 warrants issued on July 2, 2024 with an expiration date of July 2, 2026 at an exercise price of $17.5 per share (the &ldquo;Existing
Warrants&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Inducement
Letter, the Holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 427,020 shares of the Company&rsquo;s
common stock at a reduced exercise price of $3.7 per share in consideration of the Company&rsquo;s agreement to issue new common stock
purchase warrants (the &ldquo;New Warrants&rdquo;), as descried below, to purchase up to an aggregate of 640,530 shares of the Company&rsquo;s
common stock (the &ldquo;New Warrant Shares&rdquo;) at an exercise price of $3.7 per share. The Company received aggregate gross proceeds
of approximately $1.6 million from the exercise of the Existing Warrants by the Holder, before deducting financial advisory fees and
other offering expenses payable by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rodman &amp; Renshaw LLC
and H.C. Wainwright &amp; Co., LLC (&ldquo;Wainwright&rdquo;) acted as financial advisors to the Company in connection with the transactions
contemplated by the Inducement Letter. Pursuant to an engagement letter with Wainwright, the Company has agreed to pay the financial
advisors a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder&rsquo;s exercise of the Existing Warrants,
as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants and $25,000 paid for non-accountable
expenses. The Company has also agreed to issue to the financial advisors or their designees warrants (the &ldquo;Inducement Placement
Agent Warrants&rdquo;) to purchase up to 29,892 shares of common stock (representing 7.0% of the Existing Warrants being exercised),
which will have the same terms as the New Warrants having a term of five years of Stockholder Approval (as defined below) except the
Inducement Placement Agent Warrants will have an exercise price equal to $4.625 per share (125% of the exercise price of the Existing
Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Warrants have an
exercise price equal to $3.70 per share. The New Warrants will be exercisable from the effective date (the &ldquo;Warrant Stockholder
Approval Date&rdquo;) of shareholder approval (&ldquo;Stockholder Approval&rdquo;), until (i) the five-year anniversary of such date
for 340,629 of the New Warrants and (ii) the twenty-four-month anniversary of such date for 299,901 of the New Warrants. The exercise
price and number of New Warrant Shares issuable upon exercise of the New Warrants is subject to appropriate adjustment in the event of
stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the
Company&rsquo;s common stock and the exercise price. On November 7, 2025, the Warrant Stockholder Approval was obtained in a special
meeting of our shareholder, resulting in the Warrant Stockholder Approval Date being such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the transactions
contemplated pursuant to the Inducement Letter occurred on September 3, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provided that the Inducement
Letter prohibited the Company from entering into an agreement to effect any issuance by the Company involving a variable rate transaction,
the Holder agreed to waive such prohibition with respect to the transactions contemplated by the ELOC Purchase Agreement as described
below, and signed an amendment to the Inducement Letter on October 9, 2025. Pursuant to such amendment, the Company issued to the Holder
10,000 warrants to purchase shares of common stock of the Company on similar terms as the Series A-1 Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being a Smaller Reporting
Company and Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &ldquo;smaller reporting
company&rdquo; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure
obligations, including, among other things, providing only two years of audited financial statements and reduced disclosure obligations
regarding executive compensation. We will remain a smaller reporting company until the last day of any fiscal year for so long as either
(1) the market value of our Common Stock held by non-affiliates does not equal or exceed $250 million as of the prior June 30th, or (2)
our annual revenues did not equal or exceed $100 million during such completed fiscal year and the market value of our Common Stock held
by non-affiliates did not equal or exceed $700 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure
obligations, it may make the comparison of our financial statements with other public companies difficult or impossible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As an emerging growth
company, we are exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory
vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer
to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform
Act of 2010, which is part of the Dodd-Frank Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 102(b)(1) of the
JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a registration statement under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;) declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the
new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period
and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have
elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different
application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of our financial statements with those of another public
company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition
period difficult or impossible because of the potential differences in accounting standards used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may remain an &ldquo;emerging
growth company&rdquo; until as late as December&nbsp;31, 2027, the fiscal year-end following the fifth anniversary of the completion
of our IPO, though we may cease to be an &ldquo;emerging growth company&rdquo; earlier under certain circumstances, including if (1)&nbsp;we
have more than $1.07&nbsp;billion in annual net revenues in any fiscal year, (2)&nbsp;we become a &ldquo;large accelerated filer,&rdquo;
with at least $700&nbsp;million of equity securities held by non-affiliates as of the end of the second quarter of that fiscal year or
(3)&nbsp;we issue more than $1.0&nbsp;billion of non-convertible debt over a three-year period. References herein to &ldquo;emerging
growth company&rdquo; are to its meaning under the Securities Act, as modified by the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    of Common Stock currently outstanding</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 66%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,747,844 shares
    of Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
    offered by the selling stockholder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">Up to (i) 10,000,000 shares of Common Stock that we may
                                    elect, in our sole discretion, to issue and sell to White Lion, from time to time from and after
                                    the commencement date under the ELOC Purchase Agreement, and subject to applicable stock exchange
                                    rules, (ii) 284,091 shares of Common Stock issuable to White Lion as commitment
shares under the ELOC Purchase Agreement (based on a conversion price of $2.64 per share, the lowest traded price of our common stock
during the 30 business days prior to the date of issuance), (iii) 87,177 shares of Common Stock
                                    issued pursuant to the PIPE Purchase Agreement and (iv) 263,997 shares of Common Stock issuable upon
                                    exercise of Pre-Funded Warrants issued pursuant to the PIPE Purchase Agreement</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
    Stockholder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the shares of our
    Common Stock are being offered by the selling stockholder. See &ldquo;Selling Stockholder&rdquo; on page 12 of this prospectus for
    more information on the selling stockholder.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
    of Distribution</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">The selling stockholder will determine when and how they will sell the Common Stock covered by this
    prospectus. See the &ldquo;Plan of Distribution&rdquo; section of this prospectus.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of Proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">We are not selling any securities under this prospectus, and will not receive any proceeds from the
    sale of Common Stock by the selling stockholder pursuant to this prospectus. We may receive up to $30.0 million in aggregate gross
    proceeds from White Lion under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
    the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from White Lion may be less than this
    amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    Factors </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Risk Factors&rdquo;
    and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully consider before deciding
    whether to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listings</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock is listed
    on the Nasdaq Capital Market under the symbol &ldquo;ASNS.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus gives effect
to a 10-for-1 reverse share split of our issued and outstanding shares of common stock (the &ldquo;Reverse Split&rdquo;), which was effected
on November 18, 2025. Except where otherwise indicated, other than in the historical financial statements and related notes incorporated
by reference into this prospectus, all share and per share data in this prospectus have been retroactively restated to reflect the Reverse
Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Delaware
in 1998. We completed our initial public offering on May 17, 2022, and our Common Stock is currently listed on the Nasdaq Capital Market
under the symbol &ldquo;ASNS.&rdquo; Our principal executive offices are located at 710 Lakeway Drive, Suite 200 Sunnyvale, CA 94085,
and our telephone number is (510)-545-1040. The information contained on our website and available through our website is not incorporated
by reference into and should not be considered a part of this prospectus, and the reference to our website in this prospectus is an inactive
textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our securities
involves a high degree of risk. You should carefully consider the risk factors set forth in our most recent Annual Report on Form 10-K
on file with the SEC, which is incorporated by reference into this prospectus, as well as the following risk factors, which supplement
or augment the risk factors set forth in our Annual Report on Form 10-K. Before making an investment decision, you should carefully consider
these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties not presently
known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and
could result in a complete loss of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>It is not possible to predict the actual number
of Common Stock we will sell under the ELOC Purchase Agreement to the selling stockholder, or the actual gross proceeds resulting from
those sales.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain limitations
in the ELOC Purchase Agreement and compliance with applicable law, we have the discretion to deliver notices to the selling stockholder
at any time throughout the term of the ELOC Purchase Agreement. It is anticipated that shares offered to the selling stockholder in this
offering will be sold over a period until 36 months from the Commencement Date, at the latest. The number of shares ultimately offered
for sale to the Selling Stockholder under this prospectus is dependent upon the number of shares we elect to sell to selling stockholder
under the ELOC Purchase Agreement. The actual number of Common Stock that are sold to the selling stockholder may depend based on a number
of factors, including the market price of our Common Stock during the sales period. Actual gross proceeds may be less than $30.0&nbsp;million,
which may impact our future liquidity. Because the price per share of each share sold to the selling stockholder will fluctuate during
the sales period, it is not currently possible to predict the number of shares that will be sold or the actual gross proceeds to be raised
in connection with those sales, if any.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, if we elect
to issue and sell to White Lion more than the 10,000,000 shares of Common Stock that are registered for resale by White Lion hereunder
pursuant to issuance under the ELOC Purchase Agreement, we must first file with the SEC one or more additional registration statements
to register under the Securities Act for resale by White Lion such additional Common Stock we wish to sell from time to time under the
ELOC Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any additional Common Stock to
White Lion under the Purchase Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><I>The issuance and/or exercisability of certain
securities issued under the ELOC Purchase Agreement and the PIPE Purchase Agreement is contingent upon us obtaining the Stockholder Approval.
If we do not obtain the Stockholder Approval, these securities may never become issuable and/or exercisable.</I>&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If it becomes necessary for
us to issue and sell to White Lion Common Stock in excess of the Exchange Cap under the ELOC Purchase Agreement in order to receive aggregate
gross proceeds equal to $30,000,000 under the ELOC Purchase Agreement, then for so long as the Exchange Cap continues to apply to issuances
and sales of Common Stock under the Purchase Agreement, we must first obtain White Lion Shareholder Approval. In addition, the exercisability
of the number of the Pre-Funded Warrants beyond the Exchange Cap is subject to obtaining shareholder approval. The Company intends to
obtain such shareholder approval concurrently with the White Lion Shareholder Approval required for the issuance of shares of Common
Stock under the ELOC Purchase Agreement beyond the Exchange Cap &nbsp;If we are unable to obtain the required shareholder approvals,
these securities will not be issuable and/or exercisable, and will have little to no value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has agreed to call
a special meeting of its stockholders to obtain White Lion Shareholder Approval within 120 days of the Commencement Date. If the Company
fails to call a special meeting within this timeframe, it shall pay liquidated damages to White Lion, as more fully described in the
ELOC Purchase Agreement. In the event White Lion Shareholder Approval is not obtained at the special meeting, the Company is obligated
to call an additional special meeting every ninety (90) days thereafter, for a total period of 360 days, until White Lion Shareholder
Approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><I>Investors who buy Common Stock in
this offering at different times will likely pay different prices.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The issuance of Common Stock to the Selling Stockholder
pursuant to the ELOC Purchase Agreement may cause substantial dilution to our existing shareholders, and the sale of such shares acquired
by the Selling Stockholder could cause the price of our Common Stock to decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering for resale
by the selling stockholder up to 10,635,265 shares of Common Stock. The selling stockholder may ultimately purchase all, some or none
of the Common Stock issuable pursuant to the ELOC Purchase Agreement and the PIPE Purchase Agreement that are the subject of this prospectus.
After the selling stockholder has acquired shares under the ELOC Purchase Agreement and the PIPE Purchase Agreement, it may sell all,
some or none of those shares. Sales to the selling stockholder by us pursuant to the ELOC Purchase Agreement and the PIPE Purchase Agreement
under this prospectus may result in substantial dilution to the interests of other holders of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The sale of a substantial
number of shares to the selling stockholder in this offering, or anticipation of such sales, could make it more difficult for us to sell
equity or equity-related securities in the future at a time and at a price that we might otherwise desire. The number of Common Stock
ultimately offered for resale by the selling stockholder under this prospectus is dependent upon the number of Common Stock issued to
the selling stockholder pursuant to the ELOC Purchase Agreement. Depending on a variety of factors, including market liquidity of our
Common Stock, the issuance of shares to the selling stockholder may cause the trading price of our Common Stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>We have broad discretion in the use of the
net proceeds we receive from the sale of shares to the Selling Stockholder and may not use them effectively.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our management will have
broad discretion in the application of the proceeds we receive from the selling stockholder pursuant to sales of Common Stock under the
ELOC Purchase Agreement, if any, including for any of the purposes described in the section entitled &ldquo;Use of Proceeds,&rdquo; and
you will not have the opportunity as part of your investment decision to assess whether our management is using the proceeds appropriately.
Because of the number and variability of factors that will determine our use of our proceeds from the selling stockholder, their ultimate
use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result
in financial losses that could have a material adverse effect on our business and cause the price of our Common Stock to decline. Pending
their use, we may invest the proceeds from the selling stockholder in short-term, investment-grade, interest-bearing securities. These
investments may not yield a favorable return to our shareholders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We will not receive any proceeds
from the sale of Common Stock by the selling stockholder pursuant to this prospectus. We may receive up to $30.0 million in aggregate
gross proceeds from White Lion under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant
to the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from White Lion may be less than this
amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The selling securityholder
will pay any underwriting fees, discounts, selling commissions, stock transfer taxes, and certain legal expenses incurred by it in disposing
of its shares of Common Stock, and we will bear all other costs, fees, and expenses incurred in effecting the registration of such securities
covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees, and fees and expenses
of our counsel and our independent registered public accountants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="a_014"></A>THE
WHITE LION TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Equity
Line of Credit Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On September 27, 2025, we
entered into the ELOC Purchase Agreement, with an effective date of October 1, 2025 (the &ldquo;Commencement Date&rdquo;), and the White
Lion RRA with White Lion. Pursuant to the ELOC Purchase Agreement, the Company has the right, but not the obligation to require White
Lion to purchase, from time to time, up to the Commitment Amount of $30,000,000 in aggregate gross purchase price of newly issued shares
of the Company&rsquo;s Common Stock for the 36-month period beginning on the Commencement Date, subject to certain limitations and conditions
set forth in the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company is obligated
under the ELOC Purchase Agreement and the White Lion RRA to file the Resale Registration Statement with the SEC to register the Common
Stock under the Securities Act, for the resale by White Lion of shares of Common Stock that the Company may issue to White Lion under
the ELOC Purchase Agreement and to register the Commitment Shares within five business days of the date of the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The maximum number of shares
issuable under the ELOC Purchase Agreement is subject to the Exchange Cap equal to 19.99% of the Company&rsquo;s outstanding Common Stock
as of the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has agreed to call
a special meeting to obtain White Lion Shareholder Approval within 120 days of the Commencement Date. If the Company fails to call the
special meeting within this timeframe, it shall pay liquidated damages to White Lion, as more fully described in the ELOC Purchase Agreement.
In the event White Lion Shareholder Approval is not obtained at the Special Meeting, the Company is obligated to call an additional special
meeting every ninety (90) days thereafter, for a total period of 360 days, until White Lion Shareholder Approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As consideration for White
Lion&rsquo;s irrevocable commitment to purchase the Company&rsquo;s Common Stock up to the Commitment Amount, the Company agreed to issue
Commitment Shares equal to the Commitment Amount of $750,000 divided by the lowest traded price of the Company&rsquo;s Common Stock during
the 30 business days prior to the issuance of the Commitment Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any point during the
term of the ELOC Purchase Agreement the Company fails to be listed on the Nasdaq Capital Market, the Commitment Fee Amount will increase
to $1,000,000 if remedied within six months or less, to $1,250,000 if remedied after six months but before twelve months, and $1,500,000
if not remedied within twelve months pursuant to the Delisting Penalty Provision. The Delisting Penalty Provision shall automatically
be waived on the date that is six (6) months after the later of (A) the date on which White Lion Shareholder Approval is obtained and
(B) the date on which the Resale Registration Statement has been declared effective by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the satisfaction
of certain customary conditions including, without limitation, the effectiveness of a registration statement registering the shares issuable
pursuant to the ELOC Purchase Agreement, the Company&rsquo;s right to sell shares to White Lion will commence on the Commencement Date
and extend until 36 months through the Commitment Period, unless the Company has exercised its right in full to sell shares to White
Lion under the ELOC Purchase Agreement prior to such date. During such term, subject to the terms and conditions of the ELOC Purchase
Agreement, the Company shall notify White Lion through a Purchase Notice when the Company exercises its right to sell shares (the effective
date of such notice, a &ldquo;Notice Date&rdquo;). The Purchase Notice may be a Regular Purchase Notice or a Rapid Purchase Notice, each
as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares sold
pursuant to any such notice may not exceed 40% of the Average Daily Trading Volume for the Common Stock traded on Nasdaq immediately
preceding receipt of the applicable Purchase Notice, and can be increased at any time at the sole discretion of White Lion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ELOC Purchase Agreement
prohibits the Company from directing White Lion to purchase any shares if those shares, when aggregated with all other shares then beneficially
owned by White Lion (as calculated pursuant to Section 13(d) of the Exchange Act would result in White Lion beneficially owning more
than 4.99% of the outstanding Common Stock. The beneficial ownership limitation may be increased or decreased by White Lion to any other
percentage not in excess of 9.99% upon notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under a Regular Purchase
Notice, the purchase price to be paid by White Lion for any such shares will equal 97.5% multiplied by the lower of the (i) lowest daily
VWAP of the Common Stock during the Regular Purchase Valuation Period (as such term is defined in the ELOC Purchase Agreement) or (ii)
the closing price of the Common Stock one business day prior to the delivery of the Regular Purchase Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under a Rapid Purchase Notice,
the purchase price to be paid by White Lion for any such shares will equal (i) the lowest traded price of the Common Stock on the Rapid
Purchase Notice Date with respect to Rapid Purchase Price Option 1; or (ii) 99% multiplied by the lowest traded price of the Common Stock
two hours following written confirmation of the acceptance of the Rapid Purchase Notice by White Lion with respect to Rapid Purchase
Price Option 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company may terminate
the ELOC Purchase Agreement at any time, which shall be effected by written notice being sent by the Company to White Lion. In addition,
the ELOC Purchase Agreement shall automatically terminate on the earlier of (i) the end of the Commitment Period or (ii) the date that,
pursuant to or within the meaning of any bankruptcy law, the Company commences a voluntary case or any person commences a proceeding
against the Company, a custodian is appointed for the Company or for all or substantially all of its property or the Company makes a
general assignment for the benefit of its creditors. Certain provisions of the ELOC Purchase Agreement survive termination, as described
more fully in the text of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Concurrently with the execution
of the ELOC Purchase Agreement, the Company entered into the White Lion RRA with White Lion in which the Company has agreed to register
the shares of Common Stock purchased by White Lion under the ELOC Purchase Agreement with the SEC for resale within 30 days of the execution
date of the White Lion RRA. The White Lion RRA also contains usual and customary damages provisions for failure to have the registration
statement declared effective by the SEC within the time periods specified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The ELOC Purchase Agreement
and the White Lion RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The
representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific
dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Private
Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 27, 2025, the
Company entered into the PIPE Purchase Agreement with White Lion, pursuant to which the Company agreed to issue and sell to White Lion
in a private placement (the &ldquo;Offering&rdquo;) (i) 87,177 shares of Common Stock, and (ii) Pre-Funded Warrants to purchase up to
312,823 shares of Common Stock for a purchase price of $2.125 per share of Common Stock and $2.124 per Pre-Funded Warrant, for a total
aggregate gross proceeds of approximately $850,000. The Offering closed on September 29, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the PIPE Purchase
Agreement, the Company had a right to redeem 48,826 of the shares of Common Stock at a redemption price of $0.001 per share. On October
20, 2025, the Company and White Lion entered into an amendment to the pre-funded warrant, pursuant to which, in lieu of such redemption,
the Company reduced the number shares issuable under the Pre-Funded Warrants by 48,826 shares, to 263,997.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants are
immediately exercisable at an exercise price of $0.0001 per share of Common Stock and will not expire until exercised in full. However,
the Company may not issue a number of shares of Common Stock pursuant to exercise of the Pre-Funded Warrants in an amount that will not
exceed the Exchange Cap when combined with the number of Shares issued in the Offering, before shareholder approval for further issuance
beyond the Exchange Cap is obtained. The Company intends to obtain such shareholder approval concurrently with the White Lion Shareholder
Approval required for the issuance of shares of Common Stock under the ELOC Purchase Agreement beyond the Exchange Cap.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may not effect
any exercise of the Pre-Funded Warrants, and White Lion does not have the right to exercise any portion of the Pre-Funded Warrants, if
such exercise, aggregated with all other shares then beneficially owned by White Lion (as calculated pursuant to Section 13(d) of the
Exchange Act) would result in White Lion beneficially owning more than 4.99% of the outstanding Common Stock. The beneficial ownership
limitation may be increased or decreased by White Lion to any other percentage not in excess of 9.99% upon notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
obligation to file the Resale Registration Statement described above also covers the registration of the shares of Common Stock and shares
underlying the Pre-Funded Warrants issued pursuant to the PIPE Purchase Agreement. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of Common Stock
being offered by the selling stockholder are those shares of Common Stock issued or issuable in connection with the transactions contemplated
under the ELOC Purchase Agreement and the PIPE Purchase Agreement. For additional information regarding the issuance of those shares
of Common Stock and warrants, see &ldquo;The White Lion Transaction&rdquo; above. We are registering the shares of Common Stock in order
to permit the selling stockholder to offer the shares of Common Stock for resale from time to time. The selling stockholder has not had
any material relationship with us within the past three years.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">White Lion is deemed to be
an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act with respect to the shares of Common Stock
issued or issuable in connection with the transactions contemplated under the ELOC Purchase Agreement. Any underwriters, broker-dealers,
or agents that participate in the sale of the Shares or interests therein may be &ldquo;underwriters&rdquo; within the meaning of Section
2(a)(11) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
selling stockholder and other information regarding the beneficial ownership of the shares of Common Stock by the selling stockholder.
The second column lists the number the shares of Common Stock beneficially owned by the selling stockholder, based on its ownership of
the shares of Common Stock, including shares underlying the Pre-Funded Warrants, as of November 25, 2025, assuming exercise of the Pre-Funded
Warrants held by the selling stockholder on that date, without regard to any limitations on conversions or exercises. The third column
lists the maximum number of the shares of Common Stock being offered in this prospectus by the selling stockholder. The fourth and fifth
columns list the amount of the shares of Common Stock owned after the offering, by number of the shares of Common Stock and percentage
of outstanding the shares of Common Stock (assuming for the purpose of such percentage, 1,747,844 shares outstanding as of November 21,
2025) assuming in both cases the sale of all of the shares of Common Stock offered by the selling stockholder pursuant to this prospectus,
and without regard to any limitations on conversions or exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Under the terms of the Pre-Funded
Warrants, the selling stockholder may not exercise the warrants to the extent such exercise would cause the selling stockholder, together
with its affiliates, to beneficially own a number of shares of Common Stock which would exceed 4.99%, of our then outstanding shares
of Common Stock following such exercise, excluding for purposes of such determination shares of Common Stock not yet issuable upon exercise
of the warrants which have not been exercised. The number of shares does not reflect this limitation. The selling stockholder may sell
all, some or none of their shares of Common Stock in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of <BR> Shares of <BR> Common&nbsp;Stock<BR> Owned <BR> Prior to</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum
    <BR> Number of <BR> Shares of <BR> Common&nbsp;Stock<BR> to be Sold <BR> Pursuant<BR> to this</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Beneficially<BR> Owned After
    Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of selling stockholder</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus<SUP>(3)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">White Lion Capital,
    LLC <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">351,174</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10,635,265</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            business address of White Lion Capital, LLC (&ldquo;WLC&rdquo;), is 17631 Ventura Blvd.,
                                            Suite 1008, Encino, CA 91316. WLC&rsquo;s principal business is that of a private investor.
                                            Dmitriy Slobodskiy Jr., Yash Thukral, Sam Yaffa, and Nathan Yee are the managing principals
                                            of WLC. Therefore, each of Slobodskiy Jr., Thukral, Yaffa, and Yee may be deemed to have
                                            sole voting control and investment discretion over securities beneficially owned directly
                                            by WLC and, indirectly, by WLC. The foregoing should not be construed in and of itself as
                                            an admission by Slobodskiy Jr., Thukral, Yaffa, and Yee as to beneficial ownership of the
                                            securities beneficially owned directly by WLC and, indirectly, by WLC. Slobodskiy Jr., Thukral,
                                            Yaffa, and Yee each disclaim beneficial ownership of these securities except to the extent
                                            of each of their respective pecuniary interests therein.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i) 87,177
                                                                                                                                                                 shares of Common Stock issued pursuant to the PIPE Purchase Agreement and (ii) 263,997 shares of Common Stock issuable upon the
                                                                                                                                                                 exercise of the Pre-Funded Warrants issued pursuant to the PIPE Purchase Agreement. In accordance with Rule 13d-3(d) under the
                                                                                                                                                                 Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that White Lion
                                                                                                                                                                 may be required to purchase under the ELOC Purchase Agreement, including the (i) 284,091 shares of Common Stock issuable to White
                                                                                                                                                                 Lion as commitment shares under the ELOC Purchase Agreement (based on a conversion price of $2.64 per share, the lowest traded price
                                                                                                                                                                 of our common stock during the 30 business days prior to the date of issuance) that we may be obligated to issue to White Lion under
                                                                                                                                                                 certain circumstances pursuant to the ELOC Purchase Agreement, for which we would receive no cash proceeds and (ii) 10,000,000
                                                                                                                                                                 million shares of Common Stock that we may issue and sell to White Lion for cash consideration in purchases under the ELOC Purchase
                                                                                                                                                                 Agreement from time to time, at our sole discretion, during the 36-month period commencing on the Commencement Date, because the
                                                                                                                                                                 issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the
                                                                                                                                                                 satisfaction of which are entirely outside of White Lion&rsquo;s control, including the registration statement that includes this
                                                                                                                                                                 prospectus becoming and remaining effective. Furthermore, the purchase of common stock is subject to certain agreed upon maximum
                                                                                                                                                                 amount limitations set forth in the ELOC Purchase Agreement. Also, the ELOC Purchase Agreement prohibits us from issuing and selling
                                                                                                                                                                 any shares of our common stock to White Lion to the extent such shares, when aggregated with all other shares of our common stock
                                                                                                                                                                 then beneficially owned by White Lion, would cause White Lion&rsquo;s beneficial ownership of our common stock to exceed 4.99% (the
                                                                                                                                                                 &ldquo;Beneficial Ownership Cap&rdquo;). The Purchase Agreement also prohibits us from issuing or selling shares of our common stock
                                                                                                                                                                 under the Purchase Agreement in excess of the Exchange Cap unless we obtain stockholder approval to do so, or unless sales of common
                                                                                                                                                                 stock are made at a price equal to or greater than $0.394 as required under applicable Nasdaq rules. Neither the Beneficial
                                                                                                                                                                 Ownership Cap nor the Exchange Cap (to the extent applicable under Nasdaq rules) may be amended or waived under the Purchase
                                                                                                                                                                 Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of (i) 87,177 shares of Common Stock issued pursuant to the PIPE Purchase Agreement, (ii)
                                            263,997 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants issued
                                            pursuant to the PIPE Purchase Agreement, (iii) 284,091 Commitment Shares and (iv) 10,000,000
                                            million shares of Common Stock that we may issue and sell to White Lion for cash consideration
                                            in purchases under the ELOC Purchase Agreement from time to time, at our sole discretion,
                                            during the 36-month period commencing on the Commencement Date.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DESCRIPTION OF OFFERED
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following description
is intended as a summary of our Charter and our Bylaws, each of which will become effective prior to the effectiveness of the registration
statement of which this prospectus forms a part, and which will be filed as exhibits to the registration statement of which this prospectus
forms a part, and to the applicable provisions of the DGCL. Because the following is only a summary, it does not contain all of the information
that may be important to you. For a complete description, you should refer to our Charter and Bylaws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholder may,
from time to time, sell, transfer, or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common
Stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions at fixed prices, at
prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time
of sale, or at negotiated prices. This prospectus provides you with a general description of the Common Stock the selling stockholder
may offer.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter authorizes us
to issue up to 42,803,774&nbsp;shares consisting of 30,000,000&nbsp;shares of Common Stock with a par value of $0.0001 per share, 2,803,774&nbsp;shares
of non-voting&nbsp;common stock with a par value of $0.0001 per share and 10,000,000&nbsp;shares of preferred stock with a par value
of $0.0001 per share. As of November 25, 2025, there were 52 holders of record of our Common Stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of our Common
Stock have the following rights, preferences and privileges:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of Common Stock
is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Any action at a meeting
at which a quorum is present will be decided by a majority of the voting power present in person or represented by proxy, except in the
case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividend Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Common Stock
are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for payment, subject
to the rights of holders, if any, of any class of stock having preference over the Common Stock. Any decision to pay dividends on our
Common Stock will be at the discretion of our board of directors. Our board of directors may or may not determine to declare dividends
in the future. See &ldquo;Dividend Policy.&rdquo; The board&rsquo;s determination to issue dividends will depend upon our profitability
and financial condition any contractual restrictions, restrictions imposed by applicable law and the SEC, and other factors that our
board of directors deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a voluntary
or involuntary liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably
on the basis of the number of shares held in any of the assets available for distribution after we have paid in full, or provided for
payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference over the Common Stock,
if any, have received their liquidation preferences in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Rights and Preferences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Common Stock
have no pre-emptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our
Common Stock. The rights, preferences and privileges of the holders of our Common Stock are subject to and may be adversely affected
by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. Shares of our Common
Stock are not convertible into shares of any other class of capital stock, nor are they subject to any redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully paid and nonassessable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our outstanding shares
of Common Stock are, and the shares of Common Stock to be issued in this offering will be, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue
up to 10,000,000&nbsp;shares of preferred stock. Our Charter authorizes the board to issue these shares in one or more series, to determine
the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations
and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes
per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series.
Our board of directors could, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect
the voting power and other rights of the holders of Common Stock and which could have the effect of making it more difficult for a third
party to acquire, or of discouraging a third party from attempting to acquire, a majority of our outstanding voting stock. No shares
of preferred stock are curerntly outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Charter and Bylaw Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Charter and Bylaw Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter and our Bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team, including
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board of Directors vacancies.
    </I>Our Charter provides that vacancies on the board of directors may be filled only by the affirmative vote of a majority of the
    directors then in office, irrespective of whether there is a quorum, or by a sole remaining director. Additionally, the number of
    directors to serve on our board of directors is fixed solely and exclusively by resolution duly adopted by our board of directors.
    This would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors
    by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of
    directors but promotes continuity of management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Classified Board of
    Directors. </I>In accordance with our Charter, as it will be in effect following the effectiveness of the registration statement
    of which this prospectus forms a part, our board of directors will be divided into three classes with staggered three-year&nbsp;terms.
    At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from
    the time of election and qualification until the third annual meeting following election. Our directors will be divided among the
    three classes. We expect that any additional directorships resulting from an increase in the number of directors will be distributed
    among the three classes so that, as nearly as possible, each class will consist of one-third&nbsp;of the directors. The division
    of our board of directors into three classes with staggered three-year&nbsp;terms may delay or prevent a change of our management
    or a change in control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special Meetings of
    Stockholders. </I>Our Bylaws provide that special meetings of our stockholders may be called by the board of directors acting pursuant
    to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders
    may not be called by any other person or persons.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No Cumulative Voting.
    </I>The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless the corporation&rsquo;s
    certificate of incorporation provides otherwise. Our Charter does not provide for cumulative voting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment of Charter
    and Bylaw Provisions. </I>Any amendment of our Charter requires the affirmative vote of the majority of the outstanding shares of
    capital stock entitled to vote on such amendment, and the affirmative vote of the majority of the outstanding shares of each class
    entitled to vote thereon as a class, except that the provision in the Charter regarding the staggered board may not be repealed or
    amended without the vote of the holders of not less than 80% of the Company&rsquo;s voting stock, voting as a single class. Amendments
    to our Bylaws may be executed pursuant to a resolution by the Board of Directors pursuant to an affirmative vote of a majority of
    the directors then in office, or by the affirmative vote of at least 75% of the outstanding shares of capital stock entitled to vote.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&#9679;</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware Business Combination
    Statute. </I>The Company is subject to the &ldquo;business combination&rdquo; provisions of Section&nbsp;203 of the DGCL.&nbsp;In
    general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested
    stockholder for a period of three&nbsp;years following the date such person becomes an interested stockholder, unless the business
    combination or the transaction in which such person becomes an interested stockholder is approved in a prescribed manner. Generally,
    a &ldquo;business combination&rdquo; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit
    to the interested stockholder. Generally, an &ldquo;interested stockholder&rdquo; is a person that, together with affiliates and
    associates, owns, or within three&nbsp;years prior to the determination of interested stockholder status did own, 15% or more of
    a corporation&rsquo;s voting stock. The existence of this provision may have an anti-takeover effect with respect to transactions
    not approved in advance by our Board of Directors, and the anti-takeover effect includes discouraging attempts that might result
    in a premium over the market price for the shares of our Common Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exclusive Forum. </I>Unless
    we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive
    forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of
    a fiduciary duty owed by any of our current or former directors, officers, stockholder or other employees to us or our stockholders,
    (iii)&nbsp;any action asserting a claim against the Corporation or any current or former director, officer, stockholder, employee
    or agent of the Corporation arising pursuant to any provision of the DGCL, our Charter or our Bylaws, (iv)&nbsp;any action to interpret,
    apply, enforce or determine the validity of the Company&rsquo;s Charter or Bylaws, (v)&nbsp;any action asserting a claim against
    us governed by the internal affairs doctrine or (vi)&nbsp;any action asserting an &ldquo;internal corporate claim&rdquo; as that
    term is defined in Section&nbsp;115 of the General Corporation Law. The federal district courts of the United&nbsp;States of America
    shall be the exclusive forum for the resolution of any complaint, claim or proceeding asserting a cause of action arising under the
    Exchange&nbsp;Act or the Securities Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal
    and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations
    thereunder. Stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person
    or entity purchasing or otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to have notice
    of and consented to the forum provision in our Charter. This choice of forum provision may limit a stockholder&rsquo;s ability to
    bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which
    may discourage such lawsuits against us and our directors, officers and other employees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover&nbsp;Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of the DGCL,
our Charter and our Bylaws may have the effect of delaying, deferring or discouraging another person from acquiring control of our company.
These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to
encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased
protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging
a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter established a
classified board of directors, divided in three classes with staggered three-year&nbsp;terms. Under the classified board of directors
structure, only one class of directors would be elected at each annual meeting of our stockholders, with the other classes continuing
for the remainder for their respective three-year&nbsp;terms. Under the classified board of directors structure: (i)&nbsp;directors in
Class&nbsp;I, consisting of Gideon Marks, are to stand for election at the Annual Meeting to be held in 2026; (ii)&nbsp;directors in
Class&nbsp;II, consisting of Joseph Moscovitz, are to stand for election at the annual meeting of stockholders to be held in 2027; and
(iii)&nbsp;directors in Class&nbsp;III, consisting of Israel Niv and Tuvia Barlev, are to stand for election at the annual meeting of
stockholders to be held in 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Liability, Indemnification
of officers and directors and insurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter and Bylaws contain
provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL.&nbsp;Consequently,
our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors,
except liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any breach of the director&rsquo;s
    duty of loyalty to us or our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or omission not
    in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful payments of dividends
    or unlawful stock repurchases, or redemptions as provided in Section&nbsp;174 of the DGCL; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction from which
    the director derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;ASNS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our Common Stock will be VStock Transfer, LLC.&nbsp;The transfer agent and registrar&rsquo;s address is 18 Lafayette Place, Woodmere,
NY&nbsp;11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exclusive Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter provides that,
unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole
and exclusive forum for any stockholder for (a)&nbsp;any derivative action or proceeding brought on our behalf, (b)&nbsp;any action asserting
a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any current or former director, officer, stockholder, employee
or agent of the Company to the Company or the Company&rsquo;s stockholders, (c)&nbsp;any action asserting a claim against the Corporation
or any current or former director, officer, stockholder, employee or agent of the Corporation arising pursuant to any provision of the
DGCL or the Company&rsquo;s Certificate of Incorporation or Bylaws, (d)&nbsp;any action to interpret, apply, enforce or determine the
validity of the Company&rsquo;s Certificate of Incorporation or Bylaws, or (e)&nbsp;any action asserting a claim governed by the internal
affairs doctrine or (f)&nbsp;any action asserting an &ldquo;internal corporate claim&rdquo; as that term is defined in Section&nbsp;115
of the General Corporation Law. The federal district courts of the United&nbsp;States of America shall be the exclusive forum for the
resolution of any complaint, claim or proceeding asserting a cause of action arising under the Exchange&nbsp;Act or the Securities Act.
Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought
to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders cannot waive
compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring
or holding any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provision in our
Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The choice-of-forum&nbsp;provision
may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or
its directors, officers or other employees, and may result in increased costs to a stockholder who has to bring a claim in a forum that
is not convenient to the stockholder, which may discourage such lawsuits. Although under Section&nbsp;115 of the DGCL, exclusive forum
provisions may be included in a company&rsquo;s certificate of incorporation, the enforceability of similar forum provisions in other
companies&rsquo; certificates or incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could
find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive forum provision of our Charter
inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs
associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition
and results of operations and result in a diversion of the time and resources of our management and board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover&nbsp;Provisions of the DGCL
and Charter Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain provisions of the
DGCL and certain provisions included in our Charter and Bylaws summarized below may be deemed to have an anti-takeover&nbsp;effect and
may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including
attempts that might result in a premium being paid over the market price for the shares held by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Removal of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that stockholders
may only remove a director with or without cause by a vote of no less than a majority of the shares present in person or by proxy at
the meeting and entitled to vote, voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendments to Certificate of Incorporation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain sections of our Certificate
of Incorporation require the affirmative vote of the holders of a majority of the voting power of the then outstanding shares of capital
stock of the Company entitled to vote, voting together as a single class, except that the provision in the Charter regarding the staggered
board may not be repealed or amended without the vote of the holders of not less than 80% of the Company&rsquo;s voting stock, voting
as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Staggered Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors is
divided into three classes, with regular three-year&nbsp;staggered terms. This classification system increases the difficulty of replacing
a majority of the directors and may tend to discourage a third-party&nbsp;from making a tender offer or otherwise attempting to gain
control of the Company. In addition, under Delaware law, the Certificate and the By-Laws, the Company&rsquo;s directors may be removed
from office by the stockholders only for cause and only in the manner provided for in the Certificate. These factors may maintain the
incumbency of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendments to Bylaws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter limits the abilities
of the directors and stockholders to amend our Bylaws in certain circumstances. In particular, the Bylaws may be amended only by the
vote of a majority of all of the directors then in office, or by the affirmative vote of the stockholders holding at least 75% of the
outstanding shares of capital stock entitled to vote in accordance with the provisions of the Charter, Bylaws, and the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>No Cumulative Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter does not provide
for cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Meetings of Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide that,
except as otherwise required by law, special meetings of the stockholders may be called only by an officer at the request of a majority
of our board of directors, by our Chief Executive Officer or President or by the holders of not less than 25% of the holders of stock
entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholder and
any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby
on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded or in private
transactions. These sales may be at fixed or negotiated prices. The selling stockholder may use any one or more of the following methods
when selling securities:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions
    and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the
    broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate
    the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer
    as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution
    in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through
    broker-dealers that agree with the selling stockholder to sell a specified number of such securities at a stipulated price per security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or
    settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such
    methods of sale; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted
    pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The selling stockholder may
also sell securities under Rule&nbsp;144 or any other exemption from registration under the Securities Act, if available, rather than
under this prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the selling stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from each selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of
a customary brokerage commission in compliance with FINRA Rule&nbsp;2121, and in the case of a principal transaction a markup or markdown
in compliance with FINRA Rule&nbsp;2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities or interests therein, the selling stockholder may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling
stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">White Lion is deemed to be
an &lsquo;&lsquo;underwriter&rsquo;&rsquo; within the meaning of Section 2(a)(11) of the Securities Act. White Lion has informed us that
it intends to use one or more unaffiliated registered broker-dealers to effectuate all sales, if any, of our Common Stock that it may
in the future acquire from us pursuant to the ELOC Purchase Agreement. Such sales will be made at prices and at terms then prevailing
or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of
Section 2(a)(11) of the Securities Act. White Lion has informed us that each such broker-dealer will receive commissions from White Lion
that will not exceed customary brokerage commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The resale securities will
be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain
states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules and
regulations under the Exchange&nbsp;Act, any person engaged in the distribution of the resale securities may not simultaneously engage
in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation&nbsp;M, prior
to the commencement of the distribution. In addition, the selling stockholder will be subject to applicable provisions of the Exchange&nbsp;Act
and the rules and regulations thereunder, including Regulation&nbsp;M, which may limit the timing of purchases and sales of the common
stock by the selling stockholder or any other person. We will make copies of this prospectus available to the selling stockholder and
have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule&nbsp;172 under the Securities Act).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the shares
of the Common Stock offered by this prospectus will be passed upon for us by Greenberg Traurig, LLP, New&nbsp;York, NY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024 have been so incorporated
in reliance on the report (which contains an explanatory paragraph relating to the Company&rsquo;s ability to continue as a going concern
as described in Note 1b to the financial statements) of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm
of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><B>WHERE YOU CAN FIND MORE
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a registration
statement on Form&nbsp;S-1 with the SEC under the Securities Act&nbsp;with respect to the securities offered in this prospectus. This
prospectus, which is filed as part of a registration statement, does not contain all of the information set forth in the registration
statement, some portions of which have been omitted in accordance with the SEC&rsquo;s rules and regulations. Statements made in this
prospectus as to the contents of any contract, agreement or other document referred to in this prospectus are not necessarily complete
and are qualified in their entirety by reference to each such contract, agreement or other document that is filed as an exhibit to the
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You can read our SEC filings,
including the registration statement, over the internet at the SEC&rsquo;s website. Upon completion of this offering, we will be subject
to the information reporting requirements of the Exchange&nbsp;Act, and we will file reports, proxy statements and other information
with the SEC.&nbsp;The SEC&rsquo;s website contains reports, proxy and information statements and other information regarding registrants
that file electronically with the SEC.&nbsp;The address of that site is <I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain a website
at <I>www.Actelis.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>However, the information
contained in or accessible through our website is not part of this prospectus or the registration statement of which this prospectus
forms a part, and investors should not rely on such information in making a decision to purchase our Common Stock in this offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information into this prospectus. This means that we can disclose important information to you by referring you to
another document filed separately with the SEC. The information that we incorporate by reference is considered to be part of this prospectus.
Because we are incorporating by reference our future filings with the SEC, this prospectus is continually updated and those future filings
may modify or supersede some or all of the information included or incorporated in this prospectus. This means that you must look at
all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously
incorporated by reference have been modified or superseded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus incorporates by reference the
documents listed below that have been previously filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000101376225001251/ea0234571-10k_actelis.htm">Form
    10-K</A> for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">our Quarterly Reports on&nbsp;Form
                                    10-Q&nbsp;for the quarter ended March 31, 2025 filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025042679/ea0241162-10q_actelis.htm">May
                                    13, 2025</A>; for the quarter ended June 30, 2025 filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025076747/ea0252117-10q_actelis.htm">August
                                    14, 2025</A> and for the quarter ended September 30, 2025 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025110375/ea0265008-10q_actelis.htm">November
                                    14, 2025</A>;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025009695/ea022973301-8k_actelis.htm">February
                                    4, 2025 </A>(as amended on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025013541/ea0230930-8ka1_actelis.htm">February
                                    13, 2025</A>);&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025013574/ea0230983-8k_actelis.htm">February
                                    13, 2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025020293/ea0232994-8k_actelis.htm">March 4,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000101376225003599/ea0236027-8k_actelis.htm">March 28,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025027237/ea023654901-8k_actelis.htm">April 1,
                                    2025</A>;&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025042665/ea0241810-8k_actelis.htm">May 13,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025042695/ea0241879-8k_actelis.htm">May 13,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025046475/ea024307301-8k_actelis.htm">May 21,
                                    2025</A>,&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025054496/ea0245614-8k_actelis.htm">June 16,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025061358/ea0247801-8k_actelis.htm">July 3,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025072335/ea0252023-8k_actelis.htm">August 6,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025073973/ea0252611-8k_actelis.htm">August 11,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025075676/ea0253032-8k_actelis.htm">August 13,
                                    2025</A>;&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025076756/ea0253291-8k_actelis.htm">August 14,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025079179/ea0254154-8k_actelis.htm">August 21,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025080370/ea0254418-8k_actelis.htm">August 25,
                                    2025</A>;&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025082972/ea0255463-8k_actelis.htm">September 2,
                                    2025</A>;&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025084029/ea0255758-8k_actelis.htm">September 3,
                                    2025</A>;&nbsp; <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025084298/ea0255925-8k_actelis.htm">September 4,
                                    2025</A>; <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025089006/ea0257896-8k_actelis.htm">September 18,
                                    2025</A>; <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025094380/ea0259600-8k_actelis.htm">October 1, 2025</A>; <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025095449/ea0259804-8k_actelis.htm">October
                                    2, 2025</A>; <A HREF="https://www.sec.gov/Archives/edgar/data/1141284/000121390025104399/ea026318401-8k_actelisnet.htm">October 31,
                                    2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025107623/ea0264365-8k_actelisnet.htm">November 7,
                                    2025</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025110371/ea0265395-8k_actelis.htm">November 14, 2025</A>
                                    and <A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390025110404/ea0265433-8k_actelis.htm">November 14, 2025</A>.</P>


<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our
    Common Stock, which is contained in the registration statement on&nbsp;</FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1141284/000121390022023871/ea159353-8a12b_actelis.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    8-A</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;filed with the SEC on May 4, 2022 (File
    No. 001-41375).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incorporate by reference
all future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the SEC pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act, subsequent to the date of this prospectus and prior to the termination of the
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different
information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to be modified or superseded
for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated
by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed,
except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
                                            information about us contained in this prospectus should be read together with the information
                                            in the documents incorporated by reference. You may request a copy of any or all of these
                                            filings, at no cost, by writing or telephoning us at Yoav Efron, Chief Financial Officer
                                            and Deputy Chief Executive Officer, 710 Lakeway Drive, Suite 200 Sunnyvale, CA 94085 USA,
                                            telephone number +1-510-545-1045 or by emailing us at yoave@actelis.com.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actelis Networks, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>November 28, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ 0T# 2(  A$! Q$!_\0
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M\TDL5G56&24$N:?M6O:RCHVTIR48OEZN[TV/L#XF_MBV=A%/9_#_ $S^U+H
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M$K*A$,'"(0#[6_8[_P"#S[X ?$'5M)\+_MG?L[>*?@.=0O/(/Q(^%FNK\2O
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M  G7CMBY\2>+<DC6]>()']O8/('4'/.>IR ?TD?\&/7_ "'O^"AW_8)_9O\
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91?$?BJV\-7!*@E_#]OIO.3CDY_I(H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
